Drug Profile
Research programme: cancer therapeutics - Redx Pharma
Alternative Names: Bruton's tyrosine kinase inhibitor - Redx Pharma; Indoleamine-2,3-dioxygenase inhibitor - Redx Pharma; REDX 08608; SHP2 inhibitors - Redx Pharma; Smoothened inhibitor - Redx Pharma; T-cell target agonists - Redx PharmaLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Redx Pharma
- Class Small molecules
- Mechanism of Action Protein tyrosine phosphatase non receptor type 11 antagonists; SMO protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Basal cell cancer; Solid tumours
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Solid-tumours in United Kingdom
- 28 Oct 2019 No recent reports of development identified for preclinical development in Basal-cell-cancer in United Kingdom (Topical)
- 17 Oct 2017 Early research in Solid tumours in United Kingdom before October 2017 (Redx Pharma pipeline, October 2017)